BioForce Nanosciences Q2 2026 Earnings Report

BioForce Nanosciences EPS Results

• Actual EPS: $0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

BioForce Nanosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BioForce Nanosciences Announcement Details

• Quarter: Q2 2026
• Date: 8/10/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

BioForce Nanosciences (OTCMKTS:BFNH), Inc. develops and markets precision instrumentation and proprietary technologies for the production and application of nanoscale materials. Its core platform employs nozzle-driven electrohydrodynamic processes to generate and deposit nanofibers, nanowires and nanoparticles with tight control over diameter, morphology and spatial arrangement. By tailoring electric field parameters and solution properties, the technology enables reproducible fabrication of structures at the nanometer scale.

The company’s product portfolio includes desktop electrospinning systems for nanofiber fabrication, electrospray modules for nanoparticle synthesis and integrated tools for bioprinting and surface patterning. In addition to equipment sales, BioForce Nanosciences offers contract research and custom development services, as well as licensing agreements for its intellectual property. Its technologies have been applied in areas such as drug delivery, tissue engineering, advanced filtration, composite materials and sensor development.

Serving academic institutions, government laboratories and corporate research centers, BioForce Nanosciences supports customers worldwide with training, application development and technical service. By combining instrumentation, service offerings and technology licensing, the company aims to accelerate the translation of nanomaterial innovations into practical solutions for life science, industrial and environmental applications.